The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology
Open accessAbstract
We have generated a novel transgenic mouse model on a C57BL/6J genetic background that coexpresses KM670/671NL mutated amyloid precursor protein and L166P mutated presenilin 1 under the control of a neuron-specific Thy1 promoter element (APPPS1 mice). Cerebral amyloidosis starts at 6-8 weeks and the ratio of human amyloid (A)beta42 to Abeta40 is 1.5 and 5 in pre-depositing and amyloid-depositing mice, respectively. Consistent with this ratio, extensive congophilic parenchymal amyloid but minimal amyloid angiopathy is observed. Amyloid-associated pathologies include dystrophic synaptic boutons, hyperphosphorylated tau-positive neuritic structures and robust gliosis, with neocortical microglia number increasing threefold from 1 to 8 months of age. Global neocortical neuron loss is not apparent up to 8 months of age, but local neuron loss in the dentate gyrus is observed. Because of the early onset of amyloid lesions, the defined genetic background of the model and the facile breeding characteristics, APPPS1 mice are well suited for studying therapeutic strategies and the pathomechanism of amyloidosis by cross-breeding to other genetically engineered mouse models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Activated microglia surround amyloid plaques in the brains of both human patients with AD and mouse models of Aβ amyloidosis13,15,21,22.”
From Deletion of SPI1 in microglia exacerbates amyloid pathology by impairing microglial response in Alzheimer’s disease models (2026) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“although a previous report demonstrated no sex-dependent differences in Aβ accumulation in this APPPS1–21 mouse model13”
From Deletion of SPI1 in microglia exacerbates amyloid pathology by impairing microglial response in Alzheimer’s disease models (2026) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A previous report demonstrated no sex-dependent difference in the phenotypes of APP(Swe)/PS1(L166P) mice8.”
From Effects of SPI1-mediated transcriptome remodeling on Alzheimer's disease-related phenotypes in mouse models of Aβ amyloidosis (2024) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The reactive gliosis, encompassing microgliosis and astrogliosis, are prevalent neuropathological hallmarks observed in the brains of both human AD and mouse models of Aβ amyloidosis8,15,16.”
From Effects of SPI1-mediated transcriptome remodeling on Alzheimer's disease-related phenotypes in mouse models of Aβ amyloidosis (2024) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because it has been known that there is no sex effect in this experimental group8, male and female mice were combined for statistical analyses.”
From Effects of SPI1-mediated transcriptome remodeling on Alzheimer's disease-related phenotypes in mouse models of Aβ amyloidosis (2024) · cites this paper as [8]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sample sizes were chosen based on prior publications using the APP/PS1 and P301S mouse models, which provided estimations of expected effect sizes and variance.”
From APOE4 impairs the microglial response in Alzheimer’s disease by inducing TGFβ-mediated checkpoints (2023) · cites this paper as Radde et al., 2006
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The APPPS1-21 (APPPS1) mouse line coexpresses human amyloid precursor protein harboring the K670M/ N671L familial AD mutation and presenilin 1 harboring the L166P familial AD mutation, under the control of the neuron-specific Thy1 promoter.21”
From CX3CR1 Deficiency Alters Microglial Activation and Reduces Beta-Amyloid Deposition in Two Alzheimer's Disease Mouse Models (2010) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APPPS1 mouse line coexpresses APP K670M/N671L and PS1 L166P mutations under the control of the neuronspecific Thy1 promoter and exhibits early and robust A deposition beginning at 6 -8 weeks of age in the cortex and 3-4 months of age in the hippocampus.21”
From CX3CR1 Deficiency Alters Microglial Activation and Reduces Beta-Amyloid Deposition in Two Alzheimer's Disease Mouse Models (2010) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“dozens of mouse lines overexpressing several combinations of APP and PSEN1 mutations have been created to accelerate the onset of Aβ pathologies in brains [28–30].”
From Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease (2019) · cites this paper as [30]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The APPPS1–21 mouse model used in our study starts to accumulate Aβ in the neocortex at approximately 6 to 8 weeks of age and exhibits robust Aβ accumulation and plaque deposition at 4 months of age13.”
From Deletion of SPI1 in microglia exacerbates amyloid pathology by impairing microglial response in Alzheimer’s disease models (2026) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“Abnormal activation of microglia and astrocytes is observed in the brains of AD patients15 and APPPS1–21 transgenic model mice13.”
From Deletion of SPI1 in microglia exacerbates amyloid pathology by impairing microglial response in Alzheimer’s disease models (2026) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“Amyloid-associated gliosis is consistently observed in the brains of AD patients15 and amyloidosis mouse models8,16.”
From Effects of SPI1-mediated transcriptome remodeling on Alzheimer's disease-related phenotypes in mouse models of Aβ amyloidosis (2024) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“APPPS1-21 mice overexpress a human APP with a Swedish mutation (KM670/671NL) and mutant PS1 with the L166P mutation.”
From Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid-β Amyloidosis (2011) · cites this paper as Radde et al., 2006
The cited source says what the claim attributes to it.
In the citing paper
“During submission of this manuscript, another study (Takalo et al. 2025), using the APP/PS1 model which develops an elevated Aβ42:40 (~5:1) (Radde et al. 2006), proposed that the protective variant reduced the number of plaques and overall plaque load”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Radde et al. 2006
The cited source says what the claim attributes to it.
In the citing paper
“we mated Cx3cr1 knockout mice to two different mouse models of AD that exhibit either rapid deposition of primarily A42 (the APPPS1 model) 21 or gradual deposition of primarily A40 (the R1.40 model).[22][23][24]”
From CX3CR1 Deficiency Alters Microglial Activation and Reduces Beta-Amyloid Deposition in Two Alzheimer's Disease Mouse Models (2010) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“The increased levels of CH25H mRNA and protein were also observed in the frontal cortex of 4-month-old APPPS1-21 mice bearing amyloid plaques [65] (Fig. 1c, d, e).”
From 25-Hydroxycholesterol amplifies microglial IL-1β production in an apoE isoform-dependent manner (2020) · cites this paper as [65]
In the citing paper
“the study utilized APP/PS1 and APP23 transgenic mouse models, both of which were generated through expression of mutated PS1 and/or APP under the neuron-specific Thy1 promoter element [151, 152].”
From Microglial dysfunction in brain aging and Alzheimer's disease (2014) · cites this paper as [151]
In the citing paper
“The other major limitation of these mouse models was that while some showed evidence of localized hyperphosphylated tau that may represent “pretangles”[107, 118, 151, 159], none developed neurofibrillary tangles.”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [118]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K.-H., Mistl, C., Rothacher, S., Ledermann, B., Bürki, K., Frey, P., Paganetti, P. A., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13287 · Cited by 1,507
Self-citationHolcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-097 · Cited by 1,386
Borchelt, D. R., Ratovitski, T., van Lare, J., Lee, M. K., Gonzales, V., Jenkins, N. A., Copeland, N. G., Price, D. L., & Sisodia, S. S. (1997) · Neuron · doi:10.1016/s0896-6273(00)80974-5 · Cited by 1,023
Alzheimer's Disease: Molecular Understanding Predicts Amyloid-Based Therapeutics
Selkoe, D. J., & Schenk, D. (2003) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.140248 · Cited by 829
IRIZARRY, M. C., MCNAMARA, M., FEDORCHAK, K., HSIAO, K., & HYMAN, B. T. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199709000-00002 · Cited by 649
Microglial response to amyloid plaques in APPsw transgenic mice.
Frautschy, S. A., Yang, F., Irrizarry, M., Hyman, B. T., Saido, T. C., Hsiao, K., & Cole, G. M. (1998) · Europe PMC (PubMed Central) · Cited by 592
Aβ42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice
McGowan, E., Pickford, F., Kim, J., Onstead, L., Eriksen, J., Yu, C., Skipper, L., Murphy, M. P., Beard, J., Das, P., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.06.030 · Cited by 565
Quantitative and qualitative analyses of clock drawings in Alzheimer's and Huntington's disease
Rouleau, I., Salmon, D. P., Butters, N., Kennedy, C. M., & McGuire, K. (1992) · Brain and Cognition · doi:10.1016/0278-2626(92)90112-y · Cited by 556
Neuron loss in APP transgenic mice
Calhoun, M. E., Wiederhold, K.-H., Abramowski, D., Phinney, A. L., Probst, A., Sturchler-Pierrat, C., Staufenbiel, M., Sommer, B., & Jucker, M. (1998) · Nature · doi:10.1038/27351 · Cited by 502
Self-citation
Cited by
Sorted by citations
Items 201–300 of 1,000
Varvel, N. H., Grathwohl, S. A., Degenhardt, K., Resch, C., Bosch, A., Jucker, M., & Neher, J. J. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20150478 · Cited by 99
Self-citationMechanisms of amyloid plaque pathogenesis
Fiala, J. C. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0284-8 · Cited by 99
The microbiota–microglia axis in central nervous system disorders
Mossad, O., & Erny, D. (2020) · Brain Pathology · doi:10.1111/bpa.12908 · Cited by 98
The Microbiota-Gut-Brain Axis in Health and Disease and Its Implications for Translational Research
Schächtle, M., & Rosshart, S. P. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.698172 · Cited by 99
Amyloid plaque formation precedes dendritic spine loss
Bittner, T., Burgold, S., Dorostkar, M. M., Fuhrmann, M., Wegenast‐Braun, B. M., Schmidt, B., Kretzschmar, H. A., & Herms, J. W. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1047-8 · Cited by 97
Multiple Factors Contribute to the Peripheral Induction of Cerebral -Amyloidosis
Eisele, Y. S., Fritschi, S. K., Hamaguchi, T., Obermüller, U., Füger, P., Skodras, A., Schafer, C., Odenthal, J., Heikenwälder, M. F., Staufenbiel, M., et al. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.1608-14.2014 · Cited by 94
Self-citationAβ accumulation in choroid plexus is associated with mitochondrial-induced apoptosis
Vargas, T., Ugalde, C., Spuch, C., Antequera, D., Morán, M., Martín, M. A., Ferrer, I., Bermejo‐Pareja, F., & Carro, E. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.08.017 · Cited by 93
Crosstalk between endoplasmic reticulum stress and brain inflammation in Alzheimer's disease
Santos, L. E., & Ferreira, S. T. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.016 · Cited by 93
Moutinho, M., Puntambekar, S. S., Tsai, A. P., Coronel, I., Lin, P. B., Casali, B. T., Martinez, P., Oblak, A. L., Lasagna-Reeves, C. A., Lamb, B. T., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl7634 · Cited by 92
Park, H., Cho, B., Kim, H., Saito, T., Saido, T. C., Won, K.-J., & Kim, J. (2023) · Nature Communications · doi:10.1038/s41467-023-36519-8 · Cited by 92
Paul, B. D., & Snyder, S. H. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01315 · Cited by 92
Neurogenesis and Alterations of Neural Stem Cells in Mouse Models of Cerebral Amyloidosis
Ermini, F., Grathwohl, S. A., Radde, R., Yamaguchi, M., Staufenbiel, M., Palmer, T. D., & Jucker, M. (2008) · American Journal Of Pathology · doi:10.2353/ajpath.2008.060520 · Cited by 92
Self-citationHuang, Y., Skwarek‐Maruszewska, A., Horré, K., Vandewyer, E., Wolfs, L., Snellinx, A., Saito, T., Radaelli, E., Corthout, N., Colombelli, J., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab3492 · Cited by 92
Ugalde, C. L., Finkelstein, D. I., Lawson, V. A., & Hill, A. F. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13772 · Cited by 92
Hellwig, S., Masuch, A., Nestel, S., Katzmarski, N., Meyer-Luehmann, M., & Biber, K. (2015) · Scientific Reports · doi:10.1038/srep14624 · Cited by 91
Microglial morphology in Alzheimer’s disease and after Aβ immunotherapy
Franco-Bocanegra, D., Gourari, Y., McAuley, C., Chatelet, D. S., Johnston, D. A., Nicoll, J. A. R., & Boche, D. (2021) · Scientific Reports · doi:10.1038/s41598-021-95535-0 · Cited by 91
Rosenzweig, N., Kleemann, K. L., Rust, T., Carpenter, M., Grucci, M., Aronchik, M., Brouwer, N., Valenbreder, I., Cooper-Hohn, J., Iyer, M., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03122-3 · Cited by 90
Disruption of normal circadian clock function in a mouse model of tauopathy
Stevanovic, K. D., Yunus, A., Joly‐Amado, A., Gordon, M. N., Morgan, D., Gulick, D., & Gamsby, J. J. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.04.015 · Cited by 91
Mlodzianoski, M. J., Cheng-Hathaway, P. J., Bemiller, S. M., McCray, T. J., Liu, S., Miller, D. A., Lamb, B. T., Landreth, G. E., & Huang, F. (2018) · Nature Methods · doi:10.1038/s41592-018-0053-8 · Cited by 90
β-Amyloid Prions and the Pathobiology of Alzheimer’s DiseasePreprint
Watts, J. C., & Prusiner, S. B. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a023507 · Cited by 90
Early and Rapid Engraftment of Bone Marrow-Derived Microglia in Scrapie
Priller, J., Prinz, M., Heikenwälder, M. F., Zeller, N., Schwarz, P., Heppner, F. L., & Aguzzi, A. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.2275-06.2006 · Cited by 89
Claes, C., Daele, J. V. D., Boon, R., Schouteden, S., Colombo, A. V., Monasor, L. S., Fiers, M. W. E. J., Ordovás, L., Nami, F., Bohrmann, B., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.09.006 · Cited by 88
Hofrichter, J., Krohn, M., Schumacher, T., Lange, C., Feistel, B., Walbroel, B., Heinze, H., Crockett, S. L., Sharbel, T. F., & Pahnke, J. (2013) · Current Alzheimer Research · doi:10.2174/15672050113106660171 · Cited by 88
Brain-specific repression of AMPKα1 alleviates pathophysiology in Alzheimer’s model mice
Zimmermann, H. R., Yang, W., Kasica, N. P., Zhou, X., Wang, X., Beckelman, B. C., Lee, J., Furdui, C. M., Keene, C. D., & Ma, T. (2020) · Journal of Clinical Investigation · doi:10.1172/jci133982 · Cited by 86
The role of astrocytic α7 nicotinic acetylcholine receptors in Alzheimer disease
Fontana, I. C., Kumar, A., & Nordberg, A. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00792-4 · Cited by 86
Jackson, R. J., Keiser, M. S., Meltzer, J. C., Fykstra, D. P., Dierksmeier, S. E., Hajizadeh, S., Kreuzer, J., Morris, R., Melloni, A., Nakajima, T., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.03.024 · Cited by 86
BACE1 inhibition more effectively suppresses initiation than progression of β-amyloid pathology
Peters, F., Salihoglu, H., Rodrigues, E. F., Herzog, É., Blume, T., Filser, S., Dorostkar, M. M., Shimshek, D. R., Brose, N., Neumann, U., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-017-1804-9 · Cited by 86
Dodiya, H. B., Frith, M., Sidebottom, A. M., Cao, Y., Koval, J., Chang, E. B., & Sisodia, S. S. (2020) · Scientific Reports · doi:10.1038/s41598-020-64797-5 · Cited by 86
Hollnagel, J., Elzoheiry, S., Gorgas, K., Kins, S., Beretta, C. A., Kirsch, J., Kuhse, J., Kann, O., & Kiss, É. (2019) · PLoS ONE · doi:10.1371/journal.pone.0209228 · Cited by 84
Multiscale optical and optoacoustic imaging of amyloid-β deposits in mice
Ni, R., Chen, Z., Deán‐Ben, X. L., Voigt, F. F., Kirschenbaum, D. S., Shi, G., Villois, A., Zhou, Q., Crimi, A., Arosio, P., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00906-1 · Cited by 84
Pereson, S., Wils, H., Kleinberger, G., McGowan, E. M., Vandewoestyne, M., Broeck, B. V., Joris, G., Cuijt, I., Deforce, D. L. D., Hutton, M. L., et al. (2009) · The Journal of Pathology · doi:10.1002/path.2580 · Cited by 84
Murine models of Alzheimer's disease and their use in developing immunotherapies
Wısnıewskı, T., & Sigurdsson, E. M. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.05.004 · Cited by 84
Fisher, Y., Nemirovsky, A., Baron, R., & Monsonego, A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010830 · Cited by 83
Martínez-Frailes, C., Di Lauro, C., Bianchi, C., de Diego-García, L., Sebastián-Serrano, Á., Boscá, L., & Díaz-Hernández, M. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00143 · Cited by 83
The value of incomplete mouse models of Alzheimer’s disease
Radde, R., Duma, C. C., Goedert, M., & Jucker, M. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0704-y · Cited by 83
Self-citationNuclear Translocation Uncovers the Amyloid Peptide Aβ42 as a Regulator of Gene Transcription*
Barucker, C., Harmeier, A., Weiske, J., Fauler, B., Albring, K. F., Prokop, S., Hildebrand, P. W., Lurz, R., Heppner, F. L., Huber, O., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.564690 · Cited by 83
Resting State fMRI Reveals Diminished Functional Connectivity in a Mouse Model of Amyloidosis
Shah, D., Jonckers, E., Praet, J., Vanhoutte, G., Delgado y Palacios, R., Bigot, C., D’Souza, D. V., Verhoye, M., & Van der Linden, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084241 · Cited by 82
Imaging of cerebrovascular pathology in animal models of Alzheimer's disease
Klohs, J., Rudin, M., Shimshek, D. R., & Beckmann, N. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00032 · Cited by 82
Jarre, A., Gowert, N. S., Donner, L., Münzer, P., Klier, M., Borst, O., Schaller, M., Lang, F. J. W., Korth, C., & Elvers, M. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.05.019 · Cited by 82
Inhibition of the Self-Assembly of Aβ and of Tau by Polyphenols: Mechanistic Studies
Zheng, Q., Kebede, M. T., Kemeh, M. M., Islam, S., Lee, B., Bleck, S. D., Wurfl, L. A., & Lazo, N. D. (2019) · Molecules · doi:10.3390/molecules24122316 · Cited by 82
The role of APOE in transgenic mouse models of AD
Balu, D., Karstens, A. J., Loukenas, E., Maldonado Weng, J., York, J. M., Valencia-Olvera, A. C., & LaDu, M. J. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134285 · Cited by 81
Physical Exercise-Induced Myokines in Neurodegenerative Diseases
Lee, B., Shin, M., Park, Y., Won, S.-Y., & Cho, K. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115795 · Cited by 79
Brenn, A., Grube, M., Jedlitschky, G., Fischer, A., Strohmeier, B., Eiden, M., Keller, M., Groschup, M. H., & Vogelgesang, S. (2014) · Brain Pathology · doi:10.1111/bpa.12069 · Cited by 79
PET imaging with [18F]AV-45 in an APP/PS1-21 murine model of amyloid plaque deposition
Poisnel, G., Dhilly, M., Moustié, O., Delamare, J., Abbas, A., Guilloteau, D., & Barré, L. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.12.024 · Cited by 79
Aβ truncated species: Implications for brain clearance mechanisms and amyloid plaque deposition
Cabrera, E., Mathews, P. M., Mezhericher, E., Beach, T. G., Deng, J., Neubert, T. A., Rostagno, A. A., & Ghiso, J. A. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.07.005 · Cited by 78
Self-citationPersistent repression of tau in the brain using engineered zinc finger protein transcription factors
Wegmann, S., DeVos, S. L., Zeitler, B., Marlen, K., Bennett, R. E., Perez-Rando, M., MacKenzie, D., Yu, Q., Commins, C., Bannon, R. N., et al. (2021) · Science Advances · doi:10.1126/sciadv.abe1611 · Cited by 77
Liao, F., Zhang, T. J., Jiang, H., Lefton, K. B., Robinson, G. O., Vassar, R., Sullivan, P. M., & Holtzman, D. M. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0250-y · Cited by 77
Human Alzheimer’s disease reactive astrocytes exhibit a loss of homeostastic gene expression
Dai, D. L., Li, M., & Lee, E. B. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01624-8 · Cited by 77
Wasén, C., Beauchamp, L. C., Vincentini, J., Li, S., LeServe, D. S., Gauthier, C. D., Lopes, J. R., Moreira, T. G., Ekwudo, M. N., Yin, Z., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47683-w · Cited by 77
The role of ryanodine receptor type 3 in a mouse model of Alzheimer disease
Liu, J., Supnet, C. B., Sun, S., Zhang, H., Good, L. B., Александровна, П. Е., & Борисович, Б. И. (2014) · Channels · doi:10.4161/chan.27471 · Cited by 77
Rupp, N. J., Wegenast‐Braun, B. M., Radde, R., Calhoun, M. E., & Jucker, M. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.08.014 · Cited by 77
Self-citationRemembering your A, B, C's: Alzheimer's disease and ABCA1
Lewandowski, C. T., Laham, M. S., & Thatcher, G. R. J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.01.011 · Cited by 76
Ginsenoside Rg1 alleviates Aβ deposition by inhibiting NADPH oxidase 2 activation in APP/PS1 mice
Zhang, H., Su, Y., Sun, Z., Chen, M., Han, Y., Li, Y., Dong, X., Ding, S., Fang, Z., Li, W., et al. (2021) · Journal of Ginseng Research · doi:10.1016/j.jgr.2021.03.003 · Cited by 76
Cameron, B., Tse, W., Lamb, R., Li, X., Lamb, B. T., & Landreth, G. E. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.1729-12.2012 · Cited by 76
Cacquevel, M., Aeschbach, L., Houacine, J., & Fraering, P. C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035133 · Cited by 75
The Role of GLP-1 in Neuronal Activity and Neurodegeneration
Hölscher, C. (2010) · Vitamins & Hormones · doi:10.1016/b978-0-12-381517-0.00013-8 · Cited by 74
Self-citationCoomaraswamy, J., Kilger, E., Wölfing, H., Schäfer, C., Kaeser, S. A., Wegenast‐Braun, B. M., Hefendehl, J. K., Wolburg, H., Mazzella, M. J., Ghiso, J. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001056107 · Cited by 74
Self-citationPreman, P., Julia, T. C. W., Calafate, S., Snellinx, A., Alfonso-Triguero, M., Corthout, N., Munck, S., Thal, D. R., Goate, A., Strooper, B. D., et al. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00487-8 · Cited by 75
A microRNA signature that correlates with cognition and is a target against cognitive decline
Islam, M. R., Kaurani, L., Berulava, T., Heilbronner, U., Budde, M., Centeno, T. P., Elerdashvili, V., Zafieriou, M., Benito, E., Sertel, S. M., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013659 · Cited by 74
Lewandowski, C. T., Maldonado Weng, J., & LaDu, M. J. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104811 · Cited by 72
Xu, Q., Su, Z., Yang, W., Zhong, M., Xian, Y., & Lin, Z. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02704-1 · Cited by 72
De novo design of a biologically active amyloid
Gallardo, R. U., Ramakers, M., Smet, F. D., Claes, F., Khodaparast, L., Khodaparast, L., Couceiro, J. R., Langenberg, T., Siemons, M., Nyström, S., et al. (2016) · Science · doi:10.1126/science.aah4949 · Cited by 72
Granzotto, A., Vissel, B., & Sensi, S. L. (2024) · eLife · doi:10.7554/elife.90633 · Cited by 71
Aβ seeds resist inactivation by formaldehyde
Fritschi, S. K., Cintron, A. F., Ye, L., Mahler, J., Bühler, A., Baumann, F., Neumann, M., Nilsson, K. P. R., Hammarström, P., Walker, L. C., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1339-2 · Cited by 71
Self-citationHarach, T., Jammes, F., Muller, C., Duthilleul, N., Cheatham, V., Zufferey, V., Cheatham, D., Lukasheva, Y. A., Lasser, T., & Bolmont, T. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.11.009 · Cited by 71
Self-citationBosch, M. E., Dodiya, H. B., Michalkiewicz, J., Lee, C., Shaik, S. M., Weigle, I. Q., Zhang, C., Osborn, J., Nambiar, A., Patel, P., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00700-w · Cited by 70
Montagne, A., Gauberti, M., Macrez, R., Jullienne, A., Briens, A., Raynaud, J.-S., Louin, G., Buisson, A., Haelewyn, B., Docagne, F., et al. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.07.018 · Cited by 70
Locci, A., Orellana, H., Rodríguez, G., Gottliebson, M., McClarty, B. M., Dominguez, S., Keszycki, R. M., & Dong, H. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113192 · Cited by 70
Lucente, J. D., Persico, G., Zhou, Z., Jin, L., Ramsey, J. J., Rutkowsky, J. M., Montgomery, C. B., Tomilov, A. A., Kim, K., Giorgio, M., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-05860-z · Cited by 70
Early Cortical Changes in Gamma Oscillations in Alzheimer’s Disease
Klein, A. S., Donoso, J. R., Kempter, R., Schmitz, D., & Beed, P. S. (2016) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2016.00083 · Cited by 70
Whittemore, K., Derevyanko, A., Martinez, P., Serrano, R., Pumarola, M., Bosch, F., & Blasco, M. A. (2019) · Aging · doi:10.18632/aging.101982 · Cited by 69
Yang, H. S., Onos, K. D., Choi, K., Keezer, K. J., Skelly, D. A., Carter, G. W., & Howell, G. R. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108739 · Cited by 69
Shimshek, D. R., Jacobson, L. H., Kolly, C., Zamurovic, N., Balavenkatraman, K. K., Morawiec, L., Kreutzer, R., Schelle, J., Jucker, M., Bertschi, B., et al. (2016) · Scientific Reports · doi:10.1038/srep21917 · Cited by 69
Self-citationActivated cofilin exacerbates tau pathology by impairing tau-mediated microtubule dynamics
Woo, J. A., Liu, T., Fang, C. C., Cazzaro, S., Kee, T. R., LePochat, P., Yrigoin, K., Penn, C., Zhao, X., Wang, X., et al. (2019) · Communications Biology · doi:10.1038/s42003-019-0359-9 · Cited by 69
Pahnke, J., Walker, L. C., Scheffler, K., & Krohn, M. (2009) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.05.006 · Cited by 68
Zhang, Z., Daniels, R., & Schluesener, H. J. (2013) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12124 · Cited by 68
APP Regulates Microglial Phenotype in a Mouse Model of Alzheimer's Disease
Manocha, G. D., Floden, A. M., Rausch, K., Kulas, J. A., McGregor, B. A., Rojanathammanee, L., Puig, K. L., Puig, K. L., Karki, S., Nichols, M. R., et al. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.4654-15.2016 · Cited by 67
Wagner, L. K., Gilling, K. E., Schormann, E., Kloetzel, P. M., Heppner, F. L., Krüger, E., & Prokop, S. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0453-5 · Cited by 67
Hippocampal Deficits in Amyloid-β-Related Rodent Models of Alzheimer’s Disease
Vyas, Y., Montgomery, J. M., & Cheyne, J. E. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00266 · Cited by 66
APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD)
Lalonde, R., Fukuchi, K., & Strazielle, C. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.02.011 · Cited by 66
Th1 Polarization of T Cells Injected into the Cerebrospinal Fluid Induces Brain Immunosurveillance
Fisher, Y., Strominger, I., Biton, S., Nemirovsky, A., Baron, R., & Monsonego, A. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301707 · Cited by 67
Helin, J. S., Lopez‐Picon, F. R., Majidi, R. A., Eskola, O., Krzyczmonik, A., Keller, T., Löyttyniemi, E., Solin, O. H., Rinne, J. O., & Haaparanta‐Solin, M. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16677990 · Cited by 66
Latta‐Mahieu, M., Elmer, B. M., Bretteville, A., Wang, Y., Lopez‐Grancha, M., Goniot, P., Moindrot, N., Ferrari, P., Blanc, V., Schussler, N., et al. (2017) · Glia · doi:10.1002/glia.23260 · Cited by 66
Sakakibara, Y., Sekiya, M., Saito, T., Saido, T. C., & Iijima, K. M. (2019) · BMC Neuroscience · doi:10.1186/s12868-019-0496-6 · Cited by 65
Hansen, H. H., Fabricius, K., Barkholt, P., Wismann, P., Schlumberger, C., Jelsing, J., Terwel, D., Termont, A., Pyke, C., Knudsen, L. B., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158205 · Cited by 65
Manji, Z., Rojas, A., Wang, W., Dingledine, R. J., Varvel, N. H., & Ganesh, T. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180678 · Cited by 65
Harcha, P. A., Vargas, A., Yi, C., Koulakoff, A., Giaume, C., & Sáez, J. C. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.3686-14.2015 · Cited by 64
van Groen, T., Kadish, I., Wiesehan, K., Funke, S. A., & Willbold, D. (2008) · ChemMedChem · doi:10.1002/cmdc.200800289 · Cited by 64
Ettcheto, M., Petrov, D., Pedrós, I., Alva, N., Carbonell, T., Beas‐Zárate, C., Pallàs, M., Auladell, C., Folch, J., & Camins, A. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160150 · Cited by 64
High plasticity of axonal pathology in Alzheimer’s disease mouse models
Blázquez‐Llorca, L., Valero-Freitag, S., Rodrigues, E. F., Merchán-Pérez, Á., Rodríguez, J., Dorostkar, M. M., DeFelipe, J., & Herms, J. W. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0415-y · Cited by 64
Zhao, N., Yan, Q.-W., Xia, J., Zhang, X., Li, B., Yin, L., & Xu, B. (2020) · Neurochemical Research · doi:10.1007/s11064-020-03003-4 · Cited by 64
The Immune System's Role in the Consequences of Mild Traumatic Brain Injury (Concussion)
Verboon, L. N., Patel, H. C., & Greenhalgh, A. D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.620698 · Cited by 63
Zou, C., Montagna, E., Shi, Y., Peters, F., Blázquez‐Llorca, L., Shi, S., Filser, S., Dorostkar, M. M., & Herms, J. W. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1421-4 · Cited by 63
Inactivation of brain Cofilin-1 by age, Alzheimer's disease and γ-secretase
Barone, E., Mosser, S., & Fraering, P. C. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.10.004 · Cited by 63
Chronic 5-HT4 receptor activation decreases Aβ production and deposition in hAPP/PS1 mice
Tesseur, I. C., Pimenova, A. A., Lo, A. C., Ciesielska, M., Lichtenthaler, S. F., Maeyer, J. H. D., Schuurkes, J. A. J., D’Hooge, R., & Strooper, B. D. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.01.020 · Cited by 63
Revisiting rodent models: Octodon degus as Alzheimer’s disease model?
Steffen, J., Krohn, M., Paarmann, K., Schwitlick, C., Brüning, T., Marreiros, R., Müller-Schiffmann, A., Korth, C., Braun, K., & Pahnke, J. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0363-y · Cited by 62
Lutz, D., Wolters‐Eisfeld, G., Joshi, G., Djogo, N., Jakovčevski, I., Schachner, M., & KLEENE, R. B. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.346759 · Cited by 62
Evaluating β-amyloidosis progression in Alzheimer’s disease with Mueller polarimetry
Borovkova, M. A., Bykov, A. V., Popov, A., Pierangelo, A., Novikova, T., Pahnke, J., & Meglinski, I. V. (2020) · Biomedical Optics Express · doi:10.1364/boe.396294 · Cited by 62
Mitochondrial DNA polymorphisms specifically modify cerebral β-amyloid proteostasis
Scheffler, K., Krohn, M., Dunkelmann, T., Stenzel, J., Miroux, B., Ibrahim, S. M., Halbach, O. V. B. U., Heinze, H., Walker, L. C., Gsponer, J. A., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0980-x · Cited by 61
Ramalho, R. M., Nunes, A. F., Dias, R. B., Amaral, J. D., Lo, A. C., D’Hooge, R., Sebastião, A. M., & Rodrigues, C. M. P. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.04.018 · Cited by 60
Metadata
- Authors
- Radde, R., Bolmont, T., Kaeser, S. A., Coomaraswamy, J., Lindau, D., Stoltze, L., Calhoun, M. E., Jäggi, F., Wolburg, H., Gengler, S., Haass, C., Ghetti, B., Czech, C., Hölscher, C., Mathews, P. M., & Jucker, M.
- Affiliations
- Hertie Institute for Clinical Brain Research (DE)
- University of Basel (CH)
- University of Tübingen (DE)
- University of Ulster (GB)
- Adolf-Butenandt-Institut für Physiologische Chemie, Physikalische Biochemie und Zellbiologie (DE)
- Indiana University School of Medicine (US)
- F. Hoffmann-La Roche AG (CH)
- New York University (US)
- Corresponding author
- Jucker, Mathias
- ORCID
- Venue
- The EMBO Reports
- Published
- 2006-08-11
- Volume
- 7
- Issue
- 9
- Pages
- 940-946
- ISSN
- 1469-221X (ISSN-L)
- 1469-3178
- PMC
- PMC1559665
- OpenAlex
- W2156788921
- Cited by
- 986
- References
- 32
- Citations by year
- 2026: 33 · 2025: 60 · 2024: 75 · 2023: 85 · 2022: 73 · 2021: 86 · 2020: 93 · 2019: 79 · 2018: 58 · 2017: 41 · 2016: 46 · 2015: 41 · 2014: 36 · 2013: 50 · 2012: 37
- FWCI
- 9.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- EMBO Reports (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- Funders
- European Commission (LSHM-CT-2003-503330)
- Boehringer Ingelheim Stiftung
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- cerebral amyloidosis, amyloid-beta 42, amyloid angiopathy, tau hyperphosphorylation, gliosis, microglia, Alzheimer's disease model
- MeSH terms
- Animals, Cognition, Disease Models, Animal, Inflammation, Male, Membrane Proteins, Mice, Inbred C57BL, Mice, Transgenic, Neurons, Peptide Fragments, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Cerebral Amyloid Angiopathy, Neocortex, Mice, Presenilin-1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
